In this module, Dr Carl M. Gay reviews what s on the horizon for extensive-stage SCLC, including novel biomarker-driven therapies that promise to transform management of this hard-to-treat disease and research efforts to define therapeutic SCLC subtypes.
- Provider:Clinical Care Options
- Activity Link: https://clinicaloptions.com/CE-CME/oncology/tx-advances-sclc-module/18598-27560
- Start Date: 2024-03-26 05:00:00
- End Date: 2024-03-26 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.75 hours
- Commercial Support: Source: Amgen, Inc. - Amount: 45000.0 - Is Kind Support: False Source: AstraZeneca (Any division) - Amount: 30000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest